IL23A and inflammatory bowel disease: IL-23 is a pivotal promoter for chronic intestinal inflammation, and targeting IL-23-specific p19 subunits has proven to be effective in phase 2 studies of IBD [46], which may facilitate selective blockade of intestinal lymphatic trafficking without compromising systemic immune defense [47].